SlowBull
The Business Brief MONDAY, 31 AUGUST 2026
← All stories
Markets

FDA OKs Takeda, Protagonist drug for rare blood cancer

1 source ·1 article ·2h ago

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·2h ago

FDA OKs Takeda, Protagonist drug for rare blood cancer

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.